Correspondence and inquiries concerning manuscripts should be sent to the Editor:
Dr. Bob Bortolussi
Clinical and Investigative Medicine (CIM), publishes original work in the field of Clinical Investigation. Original work includes clinical or laboratory investigations and clinical reports. Reviews include information for Continuing Medical Education (CME), narrative review articles, systematic reviews, and meta-analyses.
Manuscript Presentation and Submission
Manuscripts must be prepared and submitted in the manner described in "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" by the International Committee of Medical Journal Editors available at http://www.icmje.org/ (updated October 2004). In addition, authors should consult the PRISMA Statement (http://www.prisma-statement.org) when preparing reports of systematic reviews and meta-analyses and the CONSORT Statement (http://www.consort-statement.org) when preparing reports of randomized controlled trials.
Manuscripts, including Tables, Figures and a Covering Letter should be submitted via email directly to the Editor: Dr. Bob Bortolussi, email@example.com
As of October 1, 2016, non-members of the Canadian Society of Clinical Investigation (CSCI) must agree to pay publication charges of US$150 per published page plus US$100 per figure or illustration and US$50 per table. There is no charge for members of the CSCI to publish in CIM.
Authorship and Copyright
Authors must submit a separate Covering Letter, signed by all authors, stipulating that all persons listed as authors have contributed to preparing the manuscript, and that no person or persons other than the authors listed have contributed significantly in its preparation. Authors will be asked to transfer copyright of articles accepted for publication to the Canadian Society for Clinical Investigation. The Cover Letter of submitted manuscripts should be accompanied by letters granting permission to reproduce previously published materials or to use illustrations that may identify subjects.
The cover letter must acknowledge acceptance of page charges, suggest three (3) reviewers, and acknowledge the understanding that copyright is being signed over to CIM.
Manuscripts describing investigations carried out in humans will not be accepted for publication unless the text states, at the beginning of the Methods section, that the study has been approved by, and carried out according to the instructions of the author's institutional Human Investigations or Ethics Committee. Reports of investigations in animals will not be accepted for publication unless the text states that the study was approved by the author's institutional Animal Investigation Committee.
Privacy and Confidentiality
Patients have a right to privacy that should not be infringed without informed consent. Identifying information, including patients' names, initial, or hospital numbers should not be published in written description, photographs and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published.
Manuscripts must be typed, using Microsoft Word, doublespaced throughout, including tables and figure legends. Use left justification and 12 point font. Margins should be at least 2.5 cm (1 inch) around.
Each of the following sections must begin on a separate page: Title page, Abstract, Text, Acknowledgements, References, Tables, and Figure Legends. Pages should be numbered consecutively beginning with the title page.
Figures and tables must be provided as outlined below.
|Reports of Clinical or Laboratory Investigations:||3,000 words, 50 references|
|Clinical Reports*:||2,000 words, 25 references|
|Review Articles:||7,500 words, 100 references|
|Editorials:||1,500 words, 15 references|
*Re. clinical reports: In general, individual case reports will not be considered for publication. Exception can occur if the report provides valuable information about disease pathogenesis or otherwise significantly advances the understanding of the disease or its mangement.
• Title Page should contain the full title which should be informative and concise (max. 90 characters).
• A short running head (max. 40 characters).
• First name, middle initial, and last names of each author, with highest academic degree including fellowship.
• Name of Department(s) and Institution(s) in which the work was conducted.
• List the name, address, telephone and fax numbers, and e-mail address of the author to whom correspondence should be addressed.
• Source of all financial support from foundations, institutions, pharmaceutical and other private companies in the form of grants and awards
• The second page should contain an abstract of not more than 250 words.
• Abstracts for Reports of Investigation consist of four paragraphs labeled Purpose, Methods, Results and Conclusion. The Purpose should clearly state the primary hypothesis and the objective(s) of the study. The Methods should describethe study design (case-control, cohort study, randomized controlled trial, etc), setting, subjects (including number and selection criteria), intervention and measurements. The Results should report the main findings including numerical values. Where possible, report the estimates of dispersion (e.g., standard deviation, range, or confidence interval) and p-value. The Conclusions must relate to the primary hypothesis and must be supported by the data.
• Abstracts for Review articles should consist of four paragraphs labeled Purpose, Source, Principal findings and Conclusion.
• The text of original articles is usually, but not necessarily, divided into the following sections: Introduction, Methods, Results, Discussion.
• Introduction: Clearly state the purpose and summarize the rationale for the study. Provide only pertinent references and do not review subject
• Methods: Describe subjects, justify sample size. Identify methods, apparatus, all drugs and chemicals. Give references to established methods, including statistical methods.
• Results: Present in logical sequence and do not repeat data in the text that is provided in Tables or Figures
• Discussion: Summarize study findings, compare with existing studies, describe what is novel and its importance. End with a Conclusion relevant to the findings of the study.
• Illustrations should be submitted in electronic format.
• Electronic figures must be submitted in separate files.
• Acceptable file formats are:
a) Pixel-based line art (scans or images): Tagged Image File (TIF) format with a resolution of 300 dpi.
b) Vector-based line art (generated by Freehand, Illustrator, etc.): Encapsulated Postscript (EPS) format.
c) High-quality JPEG or other "compressed" image formats may be acceptable, but the files must be of sufficient quality for publication
• Illustrations embedded within Microsoft Word or Microsoft Powerpoint files are not suitable for publication. Submit a separate file for each figure in acceptable image format. If graphics are included as part of a Word or Powerpoint document, you will be asked to re-submit them as separate image files in high-quality TIFF, EPS, or JPEG format.
• Do NOT include the legend, figure caption, or figure number as part of the graphics in the image file. This information should be provided in a separate text document.
• For publication, illustrations are reduced to single column width of 8 cm or 3 1/8" across. Do not use a variety of boldness of axes, graph lines and lettering in one figure, or present a figure drawn to a large scale in fine lines and with small, fine lettering. Fine lines and lettering will be reduced further and may disappear altogether in the single column format.
• A legend must be provided for each illustration. Legends for several illustrations may be grouped on a single page.
Please be aware that if you do not provide a separate image file for each figure or if the images provided are not of sufficient quality, it will likely result in delaying final publication.
Manuscripts which are accepted for publication cannot be published until images of sufficient quality are provided by the authors. When the figures are printed at their optimal size for viewing (approximately 5 inches wide), they must conform to the following specifications:
- 300 dpi (dots per inch) minimum; 600 dpi is preferable
- colour or black and white
- text must be clearly legible, the equivalent of 10 point font (at least) when printed to fit within a 5 inch by 5 inch box
To test whether your figure is prepared properly, please prepare it to it's final version as you are going to submit it and then print it on your home/work printer so that the shortest dimension is at least 4 inches. If any of the lines or text are not perfectly sharp and legible, then the figure is unfit for printing.
Points to remember:
- thin lines and small text are generally very difficult to read no matter how high quality the figure
- if in doubt, use LARGER text and THICKER lines in graphs and plots
- do not use high levels of compression on the image file; we can accommodate larger files, so that should not be a concern -- our primary concern is image quality, NOT a small file size
- The optimal format for submitting bitmap image files is TIFF with LZW compression at a resolution of 300dpi for a five-inch wide image (i.e. an image width of 1500 pixels). This format is likely to result in a high-resolution image that is still a reasonable size for electronic transfer.
Each table, complete with title and footnotes, should be on a separate page. In Word, please use the table creation functions to properly define rows and columns of the tables. Do NOT use spaces or tabs to align columns of text or carriage returns to define separate rows; use the appropriate table functions instead.
CIM uses the Canadian spelling for English words. When in doubt, authors should refer to the Canadian Dictionary - Revised and Expanded Edition, Gage Educational Publishing Company.
Abbreviations must be preceded by the full term for which they stand, the first time they appear in the text.
Units of measurement
Units should conform to the Système International (SI). Authors may elect to include traditional units, in addition to the SI units.
The following sequence for symbols in both tables and figures should be used: *, †, ‡, §, ¶, ‖, **, ††, ‡‡, etc.
Footnotes occurring within text use the sequence A, B, C, etc., with the corresponding footnotes appearing at the bottom of the page.
Number references consecutively in the order in which they are first cited in the text using the sequence 1, 2, 3, etc. In the text, references should appear in square brackets.
Journal titles must be abbreviated according to the style used by the National Library of Medicine (ftp://nlmpubs.nlm.nih.gov/online/journals/ljiweb.pdf).
References to web-sites should be placed in the reference list including date last observed. Unpublished observations, including information from manuscripts submitted but not yet accepted for publication, are not acceptable as references. Abstracts are accepted only if published within the previous five years in a peer reviewed journal. Editorials, Abstracts, and Correspondence should be identified as such after the title. Copies of articles "in press" should be provided, together with a copy of the letter of acceptance, at the time of submission. List all authors.
Each manuscript received is reviewed by two or more authorities. Authors should receive a report of the review process and be given a decision on publication within six weeks of receipt of the manuscript.
• As part of your manuscript submission, an accompanying covering letter should state that:
1. The design and conduct of the work was performed by all the authors,
2. The manuscript has been written, read, and approved by all the authors,
3. The material has not been previously published, in whole or in part, and it also is not under consideration for publication elsewhere,
4. Acknowledge acceptance of page charges,
5. Suggest three (3) reviewers, and
6. Acknowledge an understanding that copyright is being signed over to CIM.
• Financial support for the work and potential conflicts of interest must be disclosed.